Top

Published in:

01-06-2013 | Erratum

Erratum to: TNF/TNFR signal transduction pathway-mediated anti-apoptosis and anti-inflammatory effects of sodium ferulate on IL-1β- induced rat osteoarthritis chondrocytes in vitro

Authors: Jun Qin, Liang Shang, An-song Ping, Jing Li, Xiao-jun Li, Hong Yu, Jacques Magdalou, Liao-bin Chen, Hui Wang

Published in: Arthritis Research & Therapy | Issue 3/2013

Excerpt

After publication of our recent article [1], it was brought to our attention that an inaccurate observation was made in the Results section. We stated that different concentrations of SF have no effect on normal chondrocytes viability. However, Figure 1 demonstrates that SF concentrations 500 and 1000 μmol/L significantly increase chondrocytes viability compared with the control group. The following sentence has now been deleted from the Results section: "All of these results show that different concentrations of SF from 125 to 1,000 μmol/l have no effect on normal chondrocyte viability". …

Qin J, Shang L, Ping A, Li J, Li X, Yu H, Magdalou J, Chen L, Wang H: TNF/TNFR signal transduction pathway-mediated anti-apoptosis and anti-inflammatory effects of sodium ferulate on IL-1β-induced rat osteoarthritis chondrocytes in vitro. Arthritis Res Ther. 2012, 14: R242-10.1186/ar4085.PubMedCentralCrossRefPubMed

Title: Erratum to: TNF/TNFR signal transduction pathway-mediated anti-apoptosis and anti-inflammatory effects of sodium ferulate on IL-1β- induced rat osteoarthritis chondrocytes in vitro
Authors: Jun Qin
Liang Shang
An-song Ping
Jing Li
Xiao-jun Li
Hong Yu
Jacques Magdalou
Liao-bin Chen
Hui Wang
Publication date: 01-06-2013
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 3/2013
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar4225

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2013

A novel in vitro bovine cartilage punch model for assessing the regeneration of focal cartilage defects with biocompatible bacterial nanocellulose

Peripheral regulatory cells immunophenotyping in Primary Sjögren's Syndrome: a cross-sectional study

Increased frequency of circulating IL-21 producing Th-cells in patients with granulomatosis with polyangiitis (GPA)

IgG subclass antibodies to human and bacterial HSP60 are not associated with disease activity and progression over time in axial spondyloarthritis

Porphyromonas gingivalis and the pathogenesis of rheumatoid arthritis: analysis of various compartments including the synovial tissue

Response to 'TNF/TNFR signal transduction pathway-mediated anti-apoptosis and anti-inflammatory effects of sodium ferulate on IL-1β-induced rat osteoarthritis chondrocytes in vitro' - authors' reply

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials